Trial Profile
Phase-II Study of Olaparib as Maintenance Therapy After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Endometrial cancer; Ovarian cancer
- Focus Therapeutic Use
- Acronyms OLATRA
- 06 Oct 2022 Status changed from completed to discontinued.
- 22 Sep 2022 Status changed from active, no longer recruiting to completed.
- 04 Aug 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.